Review





Similar Products

baseline bnp levels  (Galectin Therapeutics)
86
Galectin Therapeutics baseline bnp levels
Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
Baseline Bnp Levels, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/baseline+bnp+levels/pmc12556406-130-5-0
Average 86 stars, based on 1 article reviews
baseline bnp levels - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
baseline bnp levels  (Hamamatsu)
90
Hamamatsu baseline bnp levels
Comparison of middle-aged study participants with and without major adverse cardiovascular event during follow-up (2008–2016), Hamamatsu, Japan: Retrospective analysis.
Baseline Bnp Levels, supplied by Hamamatsu, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/baseline+bnp+levels/baseline+bnp+levels/pmc10821589-189-6-22
Average 90 stars, based on 1 article reviews
baseline bnp levels - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus BNP and the clinical model plus galectin-3. The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.

Journal: Clinical Kidney Journal

Article Title: Galectin-3 as a prognostic biomarker in haemodialysis patients with preserved or mildly reduced ejection fraction

doi: 10.1093/ckj/sfaf306

Figure Lengend Snippet: Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus BNP and the clinical model plus galectin-3. The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.

Article Snippet: Galectin-3 was also correlated with baseline BNP levels ( r = 0.229, P < .001).

Techniques: Comparison

Comparison of middle-aged study participants with and without major adverse cardiovascular event during follow-up (2008–2016), Hamamatsu, Japan: Retrospective analysis.

Journal: Preventive Medicine Reports

Article Title: Impact of medical checkup parameters on major adverse cardiovascular events in the general Japanese population

doi: 10.1016/j.pmedr.2024.102600

Figure Lengend Snippet: Comparison of middle-aged study participants with and without major adverse cardiovascular event during follow-up (2008–2016), Hamamatsu, Japan: Retrospective analysis.

Article Snippet: Kaplan-Meier analysis showing the influence of baseline BNP levels on the risk of major adverse cardiovascular events (MACE) in middle-aged study participants, Hamamatsu, Japan, 2008–2016.

Techniques: Comparison, Clinical Proteomics

Kaplan-Meier analysis showing the influence of baseline BNP levels on the risk of major adverse cardiovascular events (MACE) in middle-aged study participants, Hamamatsu, Japan, 2008–2016. Participants were divided into four groups according to the quartiles of baseline BNP levels (Q1–4). The median values and interquartile ranges are shown in the figure. Major adverse cardiovascular events are defined as cardiovascular death, non-fatal myocardial infarction, unstable angina, decompensated heart failure, stroke, and other cardiovascular events requiring hospitalization.

Journal: Preventive Medicine Reports

Article Title: Impact of medical checkup parameters on major adverse cardiovascular events in the general Japanese population

doi: 10.1016/j.pmedr.2024.102600

Figure Lengend Snippet: Kaplan-Meier analysis showing the influence of baseline BNP levels on the risk of major adverse cardiovascular events (MACE) in middle-aged study participants, Hamamatsu, Japan, 2008–2016. Participants were divided into four groups according to the quartiles of baseline BNP levels (Q1–4). The median values and interquartile ranges are shown in the figure. Major adverse cardiovascular events are defined as cardiovascular death, non-fatal myocardial infarction, unstable angina, decompensated heart failure, stroke, and other cardiovascular events requiring hospitalization.

Article Snippet: Kaplan-Meier analysis showing the influence of baseline BNP levels on the risk of major adverse cardiovascular events (MACE) in middle-aged study participants, Hamamatsu, Japan, 2008–2016.

Techniques: